Fitness & Wellness Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness & Wellness Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Researchers from Ohio State University discuss findings in cancer
July 2nd, 2008
According to a study from the United States, "Histone deacetylase (HDAC) inhibitors suppress tumor cell growth via a broad spectrum of mechanisms, which should prove advantageous in the context of cancer prevention. Here, we examined the effect of dietary administration of OSU-HDAC42, a novel HDAC inhibitor, on prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model." "Based on a series of pilot studies, an AIN-76A diet was formulated containing 208 ppm OSU-HDAC42, which was estimated to deliver similar to 25 mg/kg of drug per day to each mouse and found to cause a suppression of PC-3 xenograft tumor growth equivalent to that...
Source: Fitness & Wellness Business Week (2008-07-02)
|
